Bentsur Ron

Chairman & CEO, Director, 10% OwnerNuvectis Pharma, Inc. (NVCT) · full profile →Form 4 · filed Aug 11, 2023
Net Buying
Open-Market Buys
$4K
Open-Market Sells
$0
Net Open-Market Flow
$4K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 11, 2023Buy(P)180$14.66$3K3.2M
Aug 8, 2023Buy(P)120$14.83$2K3.2M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-090650) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.